.jpg)
.png)
All
Chicago-area cardiologist assumes role during NLA Scientific Sessions in Las Vegas JACKSONVILLE, Fla. — Alan S. Brown, MD, FNLA, officially assumed the role of National Lipid Association (NLA) President at the annual Scientific Sessions in Las Vegas on Sunday after serving for the past year... more
It is truly an honor to serve as President of the Midwest Lipid Association; following in the steps of those who have brought energy, knowledge, enthusiasm, and creativity to the role. It is a somewhat daunting responsibility! We face the continued challenge of providing... more
.color-blue{ color: #23527c; } President of the National Lipid Association for the past year. Thank you to this wonderful organization for allowing me to achieve many of the goals we set for the 2018-2019 year. As you will read below, the theme for my Presidency continues to be leadership... more
img.fac { max-width:200px; } .speaker-name { padding-top: 10px; } .img-col { margin-top: 30px; } .panel { margin-top:15px; } 2026 #NLASessions Expert Theater Lineup Expert Theaters are industry supported, non CME... more
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to... more
Telemedicine is Here to Stay Telemedicine is a valuable tool for patient care, but one that has been underused and underdeveloped for many years. When COVID-19 interrupted daily life as we knew it, telemedicine abruptly entered the mainstream of healthcare. It is estimated that provider networks... more
The Very High ASCVD Risk Category Atherosclerotic cardiovascular disease (ASCVD) risk assessment has long been simplified to only several major risk factors and only a few categories, ranging from low to very high, despite the spectrum and magnitudes of risk factors and striking cumulative... more
The American College of Cardiology/American Heart Association (ACC/AHA) Blood Cholesterol Guideline recommends high-intensity statin therapy for high-risk patients to reduce the risk of major adverse cardiovascular events (MACE).1 Despite treatment with high-intensity statins, patients... more
Following a June 2015 recommendation by the U.S Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved alirocumab for patients on maximally tolerated statin therapy with heterozygous familial hypercholesterolemia (HeFH) or with clinical... more